{"slug":"ss-31-diabetic-neuropathy","verification":{"valid":true,"entries":2,"head":"ccc007fca44e22a499e15d1ba241feff3957ae5745c5ac42116b53f5eaeb3bb3"},"energy":{"passes":2,"tokens_in":41108,"tokens_out":3232,"tokens_total":44340,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"ccc007fca44e22a499e15d1ba241feff3957ae5745c5ac42116b53f5eaeb3bb3"},"provenance":[{"ts":"2026-06-29T23:56:02.603Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Ss 31 for Diabetic Neuropathy\nSlug: ss-31-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Diabetic neuropathy\",\"condition_key\":\"diabetic-neuropathy\",\"primary_peptide\":\"ss-31\",\"peptides_in_scope\":[{\"id\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Diabetic neuropathy\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"ss-31\",\"name\":\"SS-31 (Elamipretide)\",\"section_title\":\"Why SS-31 (Elamipretide) might help you\",\"layer\":\"mitochondrial\",\"steps\":[\"You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **SS-31 (Elamipretide)** → mitochondrial\",\"section_headings\":[\"What's breaking down ","response":"{\n  \"slug\": \"ss-31-diabetic-neuropathy\",\n  \"title\": \"SS-31 (Elamipretide) for Diabetic Neuropathy: Mitochondrial Evidence Review\",\n  \"body\": \"## What's breaking down if you have Diabetic neuropathy\\n\\nDiabetic neuropathy involves progressive nerve damage linked to chronic high blood sugar. Mitochondrial dysfunction sits at the core. Hyperglycemia drives excess reactive oxygen species inside nerve cell mitochondria. This damages cardiolipin in the inner membrane, impairs electron transport, lowers ATP output, and triggers further oxidative stress plus inflammation. Over time, axons degenerate, Schwann cells suffer, and sensory, motor, or autonomic nerves lose function. The process is degenerative: breakdown outruns repair in mitochondria-rich nerve tissue. No approved peptide reverses this; management focuses on glucose control and symptom relief.\\n\\n## Why SS-31 (Elamipretide) might help you\\n\\n1. You are reading about Diabetic neuropathy — what breaks down matters before any compound name.\\n2. Therefore for you: If mitochondrial oxidative damage in nerves is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nSS-31 binds cardiolipin on the inner mitochondrial membrane. In damaged mitochondria it scavenges ROS, stabilizes membrane structure, reduces electron leak, and supports ATP production. Preclinical diabetic models show this protects cells from high-glucose injury. For someone with diabetic neuropathy the logic chain runs: if hyperglycemia has already stressed nerve mitochondria, then reducing that specific ROS burden and restoring bioenergetics could slow further axonal loss. The peptide shows no effect on healthy mitochondria, so the action is selective to stressed tissue.\\n\\n## How these fit together\\n\\nSingle-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer. If your condition profile includes a multi-peptide stack, siblings would target other layers such as inflammat","tokens_in":41108,"tokens_out":3232,"cost":0,"prev":"genesis","hash":"fc9822c5d35e741176db9c4217206664ccdedda23e7ee226a442e93a41f488f2"},{"ts":"2026-07-17T02:42:02.572Z","model":"owner","action":"voxel_divide","prompt":"","input":"ss-31-diabetic-neuropathy","response":"19 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fc9822c5d35e741176db9c4217206664ccdedda23e7ee226a442e93a41f488f2","hash":"ccc007fca44e22a499e15d1ba241feff3957ae5745c5ac42116b53f5eaeb3bb3"}]}